Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk

EGFR is a potential therapeutic target for treating bladder cancer, but has not been approved for clinical use yet. Metformin is a widely used antidiabetic drug and has demonstrated interesting anticancer effects on various cancer models, alone or in combination with chemotherapeutic drugs. The effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Mei, Huang, Yanjun, Tao, Ting, Peng, Cai-Yun, Su, Qiongli, Xu, Wanjun, Darko, Kwame Oteng, Tao, Xiaojun, Yang, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917871/
https://www.ncbi.nlm.nih.gov/pubmed/27334428
http://dx.doi.org/10.1038/srep28611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917871/
https://www.ncbi.nlm.nih.gov/pubmed/27334428
http://dx.doi.org/10.1038/srep28611

Ejemplares similares